Tweets
RT @richardPAconway
UIP is predominant radiologic pattern in RA-ILD. Contrast with our other diseases. But by no means exclusive - up to 50% of RA-ILD have a more inflammatory pattern. Important treatment implications! #RNL26 https://t.co/HmW1mz429i
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
RT @richardPAconway
Updated data on RA-ILD from Olmstead County. Cumulative incidence of 15.3% over 20 years! #RNL26 https://t.co/wVrTc3QM6Y
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
RT @ericdeinmd
Mucosal Hypothesis RA #RNL26
Demoruelle
Mucosal origins of RA?
Key sites of immune-environment interaction initiate local inflamm, becomes systemic
Link of lung inflamm/immune dysregulation - ass w/ smoking, ILD
NETs in lung drive RA path?
Gut/oral microbes drive
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Dr. Fleischman on lupus dz activity including SLEDAI, which you can use on practice. But not for practice are SLE-DAS, BILAG, BICLA, SRI-4, DORIS @RWCSmtg #RWCS26 https://t.co/7sOaE7SMht
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Advances in RA-ILD
Dr. Jeffrey Sparks gave a state of the art update on Advances in RA-ILD, many of which he and his group have played a big part in, on Saturday at RNL26.
https://t.co/xO7hBRKeqE https://t.co/rs1MS08Svl
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
RT @ericdeinmd
Mucosal Hypothesis RA #RNL26
Demoruelle
ACPA can predate RA development
Nam et al: non-specific jt pain: 42% developed RA in 12 mos
Circiumaro et al: MSK complaints 38% devel RA in 36 mo
APIPPRA: 29% at 12 mo, 37% at 24 mo, StopRA 18% in 12 mo, 33% at 36 mo https://t.co/DxGhhFL1gO
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
RT @Gibson_RheumPAC
Nearly 50% of U.S. adults may meet criteria for obesity by 2030.
For rheumatologists, it directly impacts disease activity, outcomes, and treatment response. #RNL26 https://t.co/cpy4LBBPHc
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
RT @gibson_RheumPAC
Osteoarthritis affects 600 million people worldwide—yet we still have no approved disease-modifying therapies.
A powerful opening to this talk on why OA drug development keeps missing the mark. https://t.co/wBUN3lux6X
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 4 days ago
Semaglutide ameliorates osteoarthritis via wt loss-independent mechanism. GLP-1R agonist exhibits OA chondroprotective effects in a mouse model of obesity by changing chondrocyte metabolism from glycolysis to oxidative phosphorylation via the “GLP-1R-AMPK-PFKFB3” axis.
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Study of 90 adolescents (46 w. Juvenile fibromyalgia (JFM) & 44 controls) finds that JFM pts have greater sensitivity to non-painful sensory stimuli, such as sounds and bright lights; such hypersensitivity is closely related to the severity of the disease and brain function https://t.co/KGqzRK6e4a
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
RT @richardPAconway
Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/mJSmMakSBM
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago
Rheum Cases & Guidelines
https://t.co/0zI2KRuwxa https://t.co/TBw12LFh6i
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 5 days ago


